About My Health Careers Internship MedBlogs Contact us
Medindia
LOGIN REGISTER
Advertisement

Papillary Renal Cell Carcinoma Unresponsive to Sunitinib, Says Study

by Kathy Jones on May 29, 2010 at 6:05 PM
Font : A-A+

 Papillary Renal Cell Carcinoma Unresponsive to Sunitinib, Says Study

It has emerged that of the 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have non-clear cell forms of the disease.

New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib - a standard frontline treatment for RCC. In a small but decisive Phase II trial, the researchers found that sunitinib was not effective in patients with this form of the disease. The terms clear- and non-clear cell refer to the general appearance of the cancer cells under a microscope.

Advertisement

"With clear-cell RCC, there is a lot of data," said Fox Chase Cancer Center medical oncologist Elizabeth R. Plimack, M.D., M.S., who led the study while at University of Texas MD Anderson Cancer Center and will report the results at the 46th Annual Meeting of the American Society of Clinical Oncology on Monday, June 7.

"Most large studies have involved primarily or exclusively clear-cell patients. Because data on the behavior of non-clear cell kidney cancer is lacking, the disease has been treated similarly to clear cell. Now that we're taking a hard look at how sunitinib works on non-clear cell kidney cancer, we're seeing a lot of differences between the two diseases," says Plimack.
Advertisement

Working with investigators at the University of Texas MD Anderson Cancer Center, Plimack and fellow researchers examined the response and survival rates of 23 patients with papillary RCC who were treated with sunitinib.

The study built upon prior research that showed a high response rate and improved progression-free survival and overall survival in patients with clear-cell RCC who used sunitinib to interfere with the growth of cancers cells, either slowing or stopping the development of tumors.

In the current study, patients with papillary RCC were treated with sunitinib according to a two-stage design. Following the sunitinib regimen, Plimack and her colleagues found no major responses, a median progression free survival of 1.6 months and median overall survival of 10.8 months. The best response was stable disease in eight patients. The results underscore the need to develop more effective therapies for papillary RCC.

"We really need to investigate papillary renal cell carcinoma separately from clear-cell renal cell carcinoma and aggressively pursue new agents for this rare but distinct subtype of renal cell cancer," says Plimack.



Source: Eurekalert
RAS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Emotional Healing
Psychosis Risk Related to Cat Parasite
Sedentary Behavior Precipitates Night-Time Hot Flashes
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Parkinsons Disease Surgical Treatment Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Breast Cancer Renal Cell Carcinoma 

Recommended Reading
Colo-rectal cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological ....
Breast Cancer
Breast cancer is a cancer that affects the breasts or mammary glands. Early detection and lifestyle ...
Hydronephrosis / Antenatal Counseling
Currently most pregnant women undergo one or two ultrasound scans during their pregnancy....
Renal Cell Carcinoma
Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial sta...
Vesico-Ureteric Reflux Causing UTI in Children
Bacterial infection of urinary bladder can cause pain and burning sensation while passing urine. Abn...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use